What is the recommended initial dose, titration schedule, target dose, monitoring parameters, and contraindications for using enalapril in an adult with systolic (reduced‑ejection‑fraction) heart failure?

Enalapril for Heart Failure with Reduced Ejection Fraction

Start enalapril at 2.5 mg twice daily and titrate upward every 2 weeks to a target dose of 10-20 mg twice daily (maximum 40 mg/day in divided doses), monitoring blood pressure, renal function (creatinine, potassium) 1-2 weeks after each dose increase, at 3 months, then every 6 months. 1

Initial Dosing

Begin with 2.5 mg twice daily for symptomatic heart failure patients 2, 1. This low starting dose minimizes first-dose hypotension risk, which is particularly important in heart failure patients who often have baseline low blood pressure and are volume-depleted from diuretics.

Special Populations Requiring 2.5 mg Daily (Once Daily):

• Serum creatinine >1.6 mg/dL
• Serum sodium <130 mEq/L
• Creatinine clearance ≤30 mL/min
• Patients on dialysis (dose on dialysis days) 1

Pre-Treatment Considerations:

• Reduce or withhold diuretics for 24 hours before initiating enalapril to minimize hypotension risk 3
• If diuretics cannot be stopped, use extra caution with initial dosing
• Discontinue potassium-sparing diuretics during initiation 3

Titration Schedule

Double the dose at minimum 2-week intervals until reaching target dose or maximum tolerated dose 2. The evidence-based progression is:

• 2.5 mg twice daily → 5 mg twice daily → 10 mg twice daily → 20 mg twice daily

Target dose is 10-20 mg twice daily based on landmark trials (CONSENSUS, SOLVD) that demonstrated mortality reduction 2, 4. The maximum dose studied in clinical trials was 40 mg/day in divided doses 1.

Critical Principle:

Some ACE inhibitor is better than no ACE inhibitor - if target dose cannot be achieved due to side effects, maintain the highest tolerated dose rather than discontinuing 2.

Monitoring Parameters

Timing of Monitoring:

• After initial dose: Observe under medical supervision for at least 2 hours and until blood pressure stabilizes for an additional hour 1
• During titration: Check blood pressure, renal function (creatinine), and electrolytes (potassium) 1-2 weeks after each dose increment 3
• Maintenance: At 3 months, then every 6 months 3

Acceptable Changes:

• Creatinine increase up to 50% above baseline OR up to 3 mg/dL (266 μmol/L), whichever is greater, is acceptable 2
• Potassium up to 5.5-6.0 mmol/L is acceptable 2
• Asymptomatic blood pressure reduction does not require dose adjustment 2

When to Stop Up-Titration or Reduce Dose:

• Symptomatic hypotension (dizziness, lightheadedness affecting function)
• Creatinine increase >50% or >3 mg/dL
• Potassium >6.0 mmol/L
• Substantial deterioration in renal function 2, 1

Contraindications

Absolute Contraindications:

• History of angioedema with ACE inhibitors
• Bilateral renal artery stenosis
• Pregnancy

Relative Contraindications (Seek Specialist Advice):

• Significant renal dysfunction (creatinine >2.5 mg/dL or >221 μmol/L) 2
• Hyperkalemia (>5.0 mmol/L at baseline) 2
• Symptomatic or severe asymptomatic hypotension (systolic BP <90 mmHg) 2

Common Pitfalls and Management

Hypotension:

• If symptomatic hypotension occurs, first reduce or eliminate non-essential vasodilators (nitrates, calcium channel blockers) 2
• If no signs of congestion, consider reducing diuretic dose 2
• Asymptomatic low blood pressure alone does not require intervention 2

Cough:

• ACE inhibitor-induced cough rarely requires discontinuation 2
• First exclude pulmonary edema as cause of new/worsening cough
• Only switch to ARB if cough is truly intolerable (e.g., preventing sleep) and proven related to ACE inhibitor 2

Worsening Renal Function:

• Stop nephrotoxic drugs (NSAIDs) 2, 3, 2, 3
• Stop non-essential vasodilators
• If no congestion, reduce diuretic dose
• If creatinine or potassium remain excessively elevated despite these measures, reduce ACE inhibitor dose 2

Drug Interactions to Avoid:

• NSAIDs - increase risk of renal dysfunction 3
• Potassium supplements or potassium-sparing diuretics during initiation - risk of hyperkalemia 3, 1
• Careful monitoring required if combining with aldosterone antagonists (spironolactone/eplerenone) due to hyperkalemia risk 5, 6, 7

Combination Therapy Context

ACE inhibitors are first-line therapy along with beta-blockers for all NYHA class I-IV heart failure patients with reduced ejection fraction 5, 6, 8, 7. They should be used in combination with:

• Beta-blockers (Grade A)
• Diuretics as needed for volume control
• Aldosterone antagonists for NYHA class III-IV or post-MI patients (with careful potassium monitoring)
• SGLT2 inhibitors (per contemporary guidelines) 8, 4

Note: While newer guidelines favor angiotensin receptor-neprilysin inhibitors (ARNI) over ACE inhibitors as first-line therapy 8, 4, enalapril remains an appropriate and effective option, particularly where ARNI is not available or affordable.